{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-042617","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2021-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:19.761418+00:00","generated_at":"2026-06-29T19:15:05.749549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Design Therapeutics Q2 net loss $7.6M; FA GeneTAC on track for H1 2022 clinical start","bullets":["Net loss $7.6M; R&D expenses $5.0M, G&A $2.7M; cash & investments $402.8M.","Lead FA GeneTAC program: IND-enabling data support initiation of Phase 1 trial in H1 2022.","Appointed Elizabeth Gordon, Ph.D., as SVP Regulatory Affairs; board expanded with Behanna & Prasad.","DM1 GeneTAC program preclinical data planned for H2 2021.","Well-tolerated FA GeneTAC doses in rodents/NHPs achieved CNS, heart, muscle concentrations above therapeutic threshold."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-042617","json":"https://secwatch.observer/filing/0001564590-21-042617.json","markdown":"https://secwatch.observer/filing/0001564590-21-042617.md","text":"https://secwatch.observer/filing/0001564590-21-042617.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000156459021042617/0001564590-21-042617-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000156459021042617/dsgn-8k_20210809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T19:15:05.749549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}